Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Positioning ganglioside D3 as an immunotherapeutic target in lymphangioleiomyomatosis.
[lymphangioleiomyomatosis]
Tumors
that
develop
in
lymphangioleiomyomatosis
(
LAM
)
as
a
consequence
of
biallelic
loss
of
TSC
1
or
TSC
2
gene
function
express
melanoma
differentiation
antigens
.
However
,
the
percentage
of
LAM
cells
expressing
these
melanosomal
antigens
is
limited
.
Here
,
we
report
the
overexpression
of
ganglioside
D
3
(
GD
3
)
in
LAM
.
GD
3
is
a
tumor
-associated
antigen
otherwise
found
in
melanoma
and
neuroendocrine
tumors
;
normal
expression
is
largely
restricted
to
neuronal
cells
in
the
brain
.
We
also
observed
markedly
reduced
serum
antibody
titers
to
GD
3
,
which
may
allow
for
a
population
of
GD
3
-
expressing
LAM
cells
to
expand
within
patients
.
This
is
supported
by
the
demonstrated
sensitivity
of
cultured
LAM
cells
to
complement
mediated
cytotoxicity
via
GD
3
antibodies
.
GD
3
can
serve
as
a
natural
killer
T
(
NKT
)
cell
antigen
when
presented
on
CD
1
d
molecules
expressed
on
professional
antigen-presenting
cells
.
Although
CD
1
d-expressing
monocyte
derivatives
were
present
in
situ
,
enhanced
NKT-cell
recruitment
to
LAM
lung
was
not
observed
.
Cultured
LAM
cells
retained
surface
expression
of
GD
3
over
several
passages
and
also
expressed
CD
1
d
,
implying
that
infiltrating
NKT
cells
can
be
directly
cytotoxic
toward
LAM
lung
lesions
.
Immunization
with
antibodies
to
GD
3
may
thus
be
therapeutic
in
LAM
,
and
enhancement
of
existing
NKT-cell
infiltration
may
be
effective
to
further
improve
antitumor
responses
.
Overall
,
we
hereby
establish
GD
3
as
a
suitable
target
for
immunotherapy
of
LAM
.
Diseases
Validation
Diseases presenting
"lung lesions"
symptom
congenital diaphragmatic hernia
hodgkin lymphoma, classical
lymphangioleiomyomatosis
pleomorphic liposarcoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom